三諾生物(300298.SZ):持續葡萄糖監測系統取得醫療器械註冊證
格隆匯3月31日丨三諾生物(300298.SZ)公佈,公司於近日收到國家藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》(註冊證編號:國械注準20233070435),公司自主研發的“持續葡萄糖監測系統”產品已完成註冊並獲得第三類醫療器械註冊證。
公司表示,該次“持續葡萄糖監測系統”產品醫療器械註冊證的取得標誌着公司在持續葡萄糖監測領域實現重要突破,豐富了公司糖尿病監測產品線的品類,有助於滿足市場多元化的檢測需求,建立“感知+評估+干預”的閉環,將進一步增強公司產品的綜合競爭力和市場拓展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.